Diagnostic Products & Services
All of LabPMM’s tests conform to the Standard of Care as defined by the World Health Organization and are recommended by members of the National Comprehensive Cancer Network, LeukemiaNet, and other world opinion leaders in hematology oncology.
FLT3 Mutation Detection by PCR
NPM1 Mutation Detection by PCR
AML Mutation Panel: FLT3 & NPM1 Mutation Detection by PCR
FLT3 & NPM1 Mutation Detection
LabPMM is the only reference laboratory licensed to perform testing to determine both FLT3 and NPM1 mutation status. We offer the NPM1 and the FLT3 Mutation Assays as individual stand-alone tests, and together as an AML Mutation Panel. Assessment of FLT3 mutation status in cytogenically normal AML (CN-AML) is the single most important prognostic indicator of disease outcome. NPM1 mutation status has been determined to confer some protection in cases where the FLT3 mutation is present, and in cases where there is no FLT3 mutation, presence of the NPM1 mutation portends a more favorable outcome in CN-AML.
The FLT3 & NPM1 Mutation Assays are recommended in both the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN) clinical practice guidelines. These tests are included as a Standard of Care for the majority of patient's diagnosed with AML. In patients diagnosed with acute myeloid leukemia (AML) assessment of the mutation status of these biomarkers are required to determine a patient's likelihood to benefit from chemotherapy and allogeneic stem cell transplantation. They also help predict the risk of experiencing cancer recurrence.